

5-Minute Journal Club: Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Non-Small Cell Lung Cancer — Issue 4

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Datopotamab deruxtecan (Dato-DXd) was granted FDA accelerated approval for which patients?
 - a. Those with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy
 - b. Those with advanced NSCLC who have received prior platinum-based chemotherapy and an immune checkpoint inhibitor
 - c. Those with advanced EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy
2. What is the approximate incidence of oral mucositis/stomatitis among patients with advanced NSCLC receiving Dato-DXd?
 - a. 5%
 - b. 15%
 - c. 30%
 - d. >50%
3. Which of the following adverse events is most commonly reported among patients receiving Dato-DXd?
 - a. Constipation
 - b. Mucositis/stomatitis
 - c. LVEF (left ventricular ejection fraction) reduction
 - d. Ocular surface events
 - e. Neutropenia
4. Which of the following descriptions best characterizes the study design of the TROPION-Lung14 study evaluating Dato-DXd for advanced NSCLC?
 - a. A Phase II study evaluating the combination of Dato-DXd and osimertinib for EGFR-mutated NSCLC previously treated with an EGFR tyrosine kinase inhibitor
 - b. A Phase III study evaluating the combination of Dato-DXd and osimertinib versus osimertinib monotherapy for previously untreated EGFR-mutated NSCLC
 - c. A Phase III study evaluating Dato-DXd versus platinum-based chemotherapy for EGFR-mutated NSCLC previously treated with osimertinib
5. In a subset analysis of the Phase III TROPION-Lung01 study comparing Dato-DXd to docetaxel for patients with relapsed/refractory advanced NSCLC, what was approximate median CNS progression-free survival with Dato-DXd?
 - a. 1.5 months
 - b. 3.0 months
 - c. 5.0 months
 - d. 8.0 months